Michael H. Kagey

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-line Therapy for Advanced Colorectal Adenocarcinoma: The Phase II DeFianCe Trial

Zev A. Wainberg, Keun‐Wook Lee, Jong Gwang Kim, Craig Devoe et autres

us, kr, de (code pays fourni par la source)

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Keun-Wook Lee, D. Mahalingam, Byoung Yong Shim, Inho Kim et autres

kr, us (code pays fourni par la source)

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Keun Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim et autres

kr, us (code pays fourni par la source)

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis et autres

us (code pays fourni par la source)

Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab

Ryan J. Park, Milan Parikh, Leon Pappas, Moshe Sade-Feldman et autres

us (code pays fourni par la source)

A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

David R. Wise, Russell K. Pachynski, Samuel R. Denmeade, Rahul Aggarwal et autres

us (code pays fourni par la source)

A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).

Samuel J. Klempner, Bassam Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis et autres

us (code pays fourni par la source)

Figure S1 from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment

Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf et autres

Figure S6 from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment

Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf et autres

Figure S7 from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment

Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf et autres

Figure S1 from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment

Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf et autres

Figure S2 from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment

Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf et autres